Chronic Myeloid Leukaemia (CML)

📋 Key Information Summary

📋

Chronic myeloid leukaemia (CML) is a myeloproliferative neoplasm caused by the Philadelphia chromosome — the t(9;22) reciprocal translocation producing the BCR-ABL1 fusion gene encoding a constitutively active tyrosine kinase.
The majority of patients (90–95%) present in chronic phase (CP); accelerated phase (AP) and blast phase (BP) represent disease progression and carry increasingly poor prognosis.
Typical presenting features include fatigue, weight loss, splenomegaly, and leukocytosis with a characteristic left-shifted myeloid series and basophilia on peripheral blood film.
Diagnosis requires demonstration of the Philadelphia chromosome by conventional cytogenetics or BCR-ABL1 by RT-PCR; bone marrow biopsy establishes baseline and phase classification.
Tyrosine kinase inhibitors (TKIs) — imatinib (Glivec®) — transformed CML from a fatal disease to one with near-normal life expectancy for most CP-CML patients.
Second-generation TKIs (dasatinib, nilotinib, bosutinib) are used as first-line therapy in higher-risk patients or as second-line options for imatinib resistance/intolerance.
Third-generation TKI ponatinib (Iclusig®) is reserved for T315I-mutation or multi-TKI-resistant disease, requiring Authority PBS approval.
Allogeneic stem cell transplantation (allo-SCT) remains curative but is now largely reserved for patients who fail multiple TKIs or present in blast phase.
Response milestones — complete haematological response (CHR) at 3 months, major cytogenetic response (MCyR) at 6 months, complete cytogenetic response (CCyR) at 12 months, major molecular response (MMR or MR3) at 12–18 months — guide treatment decisions.
BCR-ABL1 transcript monitoring by quantitative RT-PCR (IS) is the backbone of response assessment; values >10% IS at 3 months warrant TKI switch consideration.
Treatment-free remission (TFR) is achievable in patients with sustained deep molecular response (DMR, MR4/MR4.5 for ≥2 years) under specialist supervision.
All PBS-listed TKIs for CML are available as Restricted Benefit or Authority Required items; access is via haematologist initiation and PBS authority application.
Aboriginal and Torres Strait Islander patients may face disparities in CML outcomes related to delayed presentation, limited specialist access in remote areas, and comorbidity burden.

Introduction & Australian Epidemiology

Chronic myeloid leukaemia (CML) is a clonal myeloproliferative neoplasm (MPN) characterised by the presence of the Philadelphia (Ph) chromosome — the reciprocal translocation t(9;22)(q34;q11) — which generates the BCR-ABL1 fusion oncogene. This fusion gene encodes a constitutively active tyrosine kinase that drives uncontrolled proliferation of the granulocytic lineage, leading to accumulation of maturing and mature myeloid cells in blood, bone marrow, and extramedullary sites. The introduction of tyrosine kinase inhibitors (TKIs) in 2001 marked one of the most dramatic paradigm shifts in oncology, transforming CML from a disease with a median survival of 3–5 years to one in which most patients can expect a near-normal life expectancy.

Epidemiology in Australia

CML accounts for approximately 15% of all leukaemias in adults. In Australia, the age-standardised incidence is approximately 1.2–1.6 per 100,000 population per year, with an estimated 300–350 new diagnoses annually. The median age at diagnosis is 55–60 years, though CML can present at any age, including in paediatric patients. The incidence is slightly higher in males (M:F ratio approximately 1.4:1). Environmental risk factors are limited; prior exposure to ionising radiation is the only well-established risk factor. Most cases arise de novo without identifiable predisposing factors.

Australia's TKI access programme through the Pharmaceutical Benefits Scheme (PBS) ensures that all eligible patients can access first- and second-line TKIs at subsidised cost. The Australian CML Registry and national haematology networks (including the Australasian Leukaemia & Lymphoma Group — ALLG) have contributed significantly to international CML outcome data, confirming that Australian CML survival rates are comparable to or exceed global benchmarks.

Aboriginal and Torres Strait Islander Australians may have lower incidence of CML but are more likely to present at advanced stage and have reduced access to haematology specialists in remote and very remote regions of Australia. Tailored pathways and Telehealth-supported care are critical to closing outcome gaps.

Pathogenesis & BCR-ABL

The Philadelphia Chromosome

The hallmark of CML is the Philadelphia (Ph) chromosome — the product of a balanced reciprocal translocation between chromosomes 9 and 22: t(9;22)(q34;q11). This translocation juxtaposes the ABL1 proto-oncogene (from 9q34) with the BCR gene (from 22q11), creating a novel fusion gene BCR-ABL1 on the derivative chromosome 22q−. The Ph chromosome is present in >95% of CML patients; a minority harbour cryptic or variant translocations detectable only by fluorescence in situ hybridisation (FISH) or RT-PCR.

BCR-ABL1 Fusion Variants

The breakpoint in the BCR gene determines the size of the fusion protein:

Transcript	Breakpoint	Protein	Frequency in CML	Clinical Relevance
e13a2 (b2a2)	Major breakpoint cluster region (M-bcr)	p210	~60%	Classic CML; used for qRT-PCR monitoring
e14a2 (b3a2)	M-bcr	p210	~35–40%	Classic CML; slightly better TKI responses reported
e19a2	Micro-bcr (μ-bcr)	p230	<1%	Rare; may present with neutrophilic CML
e1a2	Minor breakpoint cluster region (m-bcr)	p190	~1–2%	Typically ALL; if in CML, may indicate monocytic differentiation

Oncogenic Mechanism

The BCR-ABL1 fusion protein has constitutive tyrosine kinase activity that activates multiple downstream signalling pathways:

RAS/MAPK pathway — drives proliferation and differentiation arrest of myeloid progenitors.
PI3K/AKT/mTOR pathway — promotes survival and anti-apoptotic signalling.
JAK/STAT pathway — supports cytokine-independent growth.
MYC and BCL-2 upregulation — sustains clonal expansion.

The net effect is expansion of a pluripotent haematopoietic stem cell clone with increased but not unlimited self-renewal capacity, explaining the chronic phase of the disease. Accumulation of additional genetic abnormalities (trisomy 8, isochromosome 17q, additional Ph chromosome, RUNX1, TP53 mutations) drives progression to accelerated and blast phases.

TKI Targeting of BCR-ABL1

TKIs competitively bind the ATP-binding pocket of the BCR-ABL1 kinase domain, blocking autophosphorylation and downstream signalling. Imatinib was the first TKI and binds in the inactive (DFG-out) conformation. Second-generation TKIs (dasatinib, nilotinib, bosutinib) have higher potency and can bind in active or inactive conformations, conferring activity against many (but not all) imatinib-resistant mutants. Ponatinib, a third-generation TKI, was designed to overcome the gatekeeper T315I mutation that confers resistance to all earlier TKIs.

⚠️

Mutation testing is essential: BCR-ABL1 kinase domain mutation analysis (by Sanger sequencing or NGS) must be performed at treatment failure or suboptimal response to guide TKI switching. The T315I mutation requires ponatinib or allo-SCT.

Clinical Features & Blood Film

Presentation in Chronic Phase

Approximately 40–50% of patients are asymptomatic at diagnosis, with CML detected incidentally on a routine full blood count (FBC). When symptomatic, the presentation is insidious and includes:

Constitutional symptoms: Fatigue, weight loss, night sweats, anorexia.
Splenomegaly: Present in 50–70% at diagnosis; may cause left upper quadrant discomfort, early satiety, or splenic infarction.
Hepatomegaly: Less common than splenomegaly; present in ~15%.
Hypermetabolic symptoms: Bone pain, gout from hyperuricaemia, priapism (rare).
Bleeding or thrombosis: Uncommon in CP; may reflect extreme thrombocytosis or platelet dysfunction.

Full Blood Count Findings

Parameter	Typical Finding at Diagnosis	Notes
WCC	Markedly elevated, often 50–300 × 10⁹/L	Can exceed 500 × 10⁹/L; correlates with splenic size
Differential	Left-shifted myeloid series; increased myelocytes, metamyelocytes	Myelocyte peak is characteristic; blasts <5% in CP
Basophils	Absolute basophilia (often >5%, sometimes >20%)	Basophilia >20% in AP criteria; an important disease marker
Eosinophils	Frequently elevated	Part of the pan-myeloid expansion
Haemoglobin	Usually normal or mildly reduced	Anaemia at presentation suggests AP/BP or unrelated cause
Platelets	Normal, elevated (sometimes >1000 × 10⁹/L), or mildly reduced	Thrombocytopenia at diagnosis is a poor prognostic sign
LDH	Elevated	Reflects tumour burden and cell turnover
Uric acid	Frequently elevated	Risk of tumour lysis with rapid cell reduction

Peripheral Blood Film

The blood film in CML has several characteristic features that can suggest the diagnosis before cytogenetic confirmation:

Leukoerythroblastic picture: Immature myeloid cells (promyelocytes, myelocytes, metamyelocytes) and occasional nucleated red cells.
Myelocyte peak: Myelocytes often exceed metamyelocytes — the so-called "CML hump" on the differential.
Basophilia: Readily visible basophils; often more prominent than expected.
Platelet morphology: Large platelets may be present; megakaryocyte fragments occasionally seen.
Absence of significant dysplasia: Unlike MDS/MPN overlap syndromes, CML cells mature relatively normally.
Blasts: Should be <5% in chronic phase; ≥10% suggests accelerated phase, ≥20% defines blast phase.

ℹ️

Pearl: The combination of a markedly elevated WCC with a left-shifted differential, prominent basophilia, and splenomegaly should prompt immediate consideration of CML and urgent cytogenetic/PCR testing.

Diagnosis & Staging (Phases)

Diagnostic Work-Up

The diagnosis of CML requires demonstration of the BCR-ABL1 fusion gene. The following investigations should be performed at baseline:

Essential

Peripheral blood with differential & blood film

Characterise leucocytosis, basophilia, blast percentage. MBS Item 65070.

Essential

Bone marrow aspirate & trephine biopsy

Cellularity, blast percentage, reticulin fibrosis grade, cytogenetics. Establish baseline cellularity and phase.

Essential

Conventional cytogenetics (karyotype)

Confirm Ph chromosome t(9;22); identify additional cytogenetic abnormalities (ACA) — prognostically important. 20 metaphases required.

Essential

BCR-ABL1 by RT-PCR (qualitative)

Identify transcript type (e13a2 vs e14a2). Establishes the PCR target for future quantitative monitoring.

Essential

BCR-ABL1 quantitative RT-PCR (IS)

Baseline transcript level on International Scale. All future results reported as %IS relative to this baseline. MBS Item 73304.

Available

FISH for BCR-ABL1 (if karyotype Ph-negative)

Confirms cryptic rearrangements in ~5% of cytogenetically Ph-negative cases.

Available

Sokal / ELTS risk score calculation

Uses age, spleen size, platelet count, blast %. Guides first-line TKI choice.

Referral

BCR-ABL1 kinase domain mutation analysis

At baseline (recommended by some centres) and mandatory at treatment failure. Sanger sequencing or NGS panel.

Available

Additional labs: LDH, urate, B12, ferritin, CRP

Supportive; elevated LDH and urate reflect disease burden.

Phase Classification (2022 WHO / ICC Criteria)

Feature	Chronic Phase (CP)	Accelerated Phase (AP)	Blast Phase (BP)
Blasts (blood + marrow)	<10%	10–19%	≥20%
Basophils (blood)	<20%	≥20%	Any
Platelets	Normal or ↑	<100 × 10⁹/L (unrelated to therapy) or >1000 × 10⁹/L unresponsive	Any
Additional cytogenetic abnormalities	None or minor	ACA in clonal evolution (trisomy 8, i(17q), +Ph, +19)	ACA may be present
Extramedullary disease	No	Granulocytic sarcoma possible	Yes; may have CNS or other extramedullary blast infiltration
Morphology	Mature differentiation	Increasing dysplasia, clusters of small megakaryocytes	Myeloid (60%), lymphoid (20–30%), mixed

Prognostic Scoring Systems

ℹ️

ELTS Score (European Treatment and Outcome Study) — now preferred over Sokal for TKI-era prognostication in CP-CML.
Variables: age, spleen size (cm below costal margin), platelet count, peripheral blood blasts (%).
Low risk: Consider imatinib first-line.
Intermediate/high risk: Consider second-generation TKI (dasatinib or nilotinib) first-line for deeper/faster responses.

Management (Imatinib, Nilotinib, Dasatinib, SCT)

First-Line TKI Therapy — Chronic Phase

TKI therapy is the standard of care for all patients with CP-CML. The choice of first-line TKI is based on risk stratification, comorbidities, patient preference, and drug interaction profile.

💊

Imatinib

Glivec® · Generics available · BCR-ABL tyrosine kinase inhibitor

Adult dose 400 mg PO once daily with food and a large glass of water

Dose escalation 600–800 mg PO daily for suboptimal response or failure (under specialist direction)

Paediatric dose 260 mg/m²/day PO (max 400 mg); for children <1 year or <10 kg: 150 mg/m²/day

Renal adjustment Reduce by 50% if CrCl <20 mL/min or on dialysis; monitor closely

Hepatic adjustment Reduce to 400 mg alternate days if bilirubin >3× ULN; use with caution in severe hepatic impairment

Key interactions CYP3A4 substrate; avoid with St John's wort, ketoconazole, grapefruit juice

Common side effects Oedema, nausea, muscle cramps, rash, diarrhoea, fatigue

Monitoring FBC weekly × 1 month then fortnightly × 2 months then monthly; LFTs; qRT-PCR every 3 months

PBS status ✔ PBS General Benefit — Authority Required for initial and continuing therapy

💊

Dasatinib

Sprycel® · BCR-ABL/SRC dual inhibitor

Adult dose (1st-line) 100 mg PO once daily (can be taken without regard to food)

Adult dose (2nd-line) 100 mg PO once daily (50 mg for resistant CML at discretion)

Paediatric dose 60 mg/m²/day PO (max 100 mg); for children ≥10 kg

Renal adjustment No dose adjustment required; limited dialysis data — use with caution

Key monitoring ECG at baseline (QTc); pleural effusion surveillance (CXR if dyspnoea); FBC for cytopenias

PBS status Restricted Benefit — Authority Required; 2nd-line after imatinib failure/intolerance OR 1st-line for high-risk CP-CML

💊

Nilotinib

Tasigna® · BCR-ABL inhibitor (imatinib analogue)

Adult dose (1st-line) 300 mg PO twice daily, taken 12 hours apart, on empty stomach (no food 2 h before or 1 h after)

Adult dose (2nd-line) 400 mg PO twice daily (same fasting requirements)

Renal adjustment No dose adjustment for renal impairment; not studied on dialysis

Key monitoring ECG at baseline, day 3, day 7, then periodically (QTc prolongation risk); lipid profile; glucose; LFTs

Contraindications QTc >450 ms; hypokalaemia/hypomagnesaemia must be corrected; avoid with CYP3A4 inhibitors

PBS status Restricted Benefit — Authority Required; 2nd-line after imatinib OR 1st-line for high-risk

💊

Bosutinib

Bosulif® · BCR-ABL/SRC inhibitor

Adult dose (2nd-line) 500 mg PO once daily with food; may reduce to 400 mg for GI intolerance

Adult dose (3rd-line) 400–500 mg PO daily per specialist discretion

Hepatic adjustment Contraindicated in severe hepatic impairment (Child-Pugh C)

PBS status Authority Required — Specialist — 2nd/3rd-line after ≥1 prior TKI failure

💊

Ponatinib

Iclusig® · Pan-BCR-ABL inhibitor (active against T315I)

Adult dose 45 mg PO once daily (reduce to 30 mg or 15 mg in responders to mitigate vascular risk)

Indications T315I mutation OR CP/AP/BP-CML resistant to ≥2 prior TKIs

Key risk Arterial occlusive events (MI, stroke, peripheral arterial disease); requires cardiovascular risk assessment

PBS status Authority Required — Specialist — T315I mutation or multi-TKI failure

Treatment Response Milestones (ELN 2020)

Response to TKI therapy is assessed at defined time points using BCR-ABL1 quantitative RT-PCR (International Scale) and, in some cases, cytogenetics:

Time Point	Optimal Response	Warning	Failure
Baseline	—	High-risk (ELTS); ACA	—
3 months	BCR-ABL1 ≤10% IS	>10% IS	No CHR or >95% Ph+ (if tested)
6 months	BCR-ABL1 ≤1% IS	1–10% IS	>10% IS or Ph+ >35%
12 months	BCR-ABL1 ≤0.1% IS (MMR/MR3)	>0.1–1% IS	>1% IS or Ph+ >0%
Then every 3 months	MMR or better	Loss of MMR; rising transcript	Loss of CHR, CCyR, or confirmed MMR loss; mutations

🚨

At treatment failure: Perform BCR-ABL1 kinase domain mutation analysis. Switch TKI based on mutation profile. T315I → ponatinib. Consider allo-SCT evaluation. Do not continue a TKI at which the patient has failed.

Management of Accelerated & Blast Phase

Accelerated phase (AP) and blast phase (BP) require more aggressive strategies:

AP-CML: TKI therapy (second-generation preferred) with the goal of returning to chronic phase; allo-SCT should be discussed early.
BP-CML: If myeloid blast crisis — TKI + AML-type induction chemotherapy (e.g., cytarabine + anthracycline). If lymphoid blast crisis — ALL-type induction (e.g., hyper-CVAD) + TKI. Allo-SCT is the only potentially curative option and should be pursued in fit patients once second chronic phase is achieved.
Ponatinib has particular efficacy in advanced-phase CML and should be considered early in BP.

Allogeneic Stem Cell Transplantation

Allo-SCT was the standard curative therapy before TKIs and remains an important option for selected patients:

Current indications: Failure of ≥2 TKIs; T315I mutation (if ponatinib unavailable or contraindicated); blast phase CML; patients with compound mutations resistant to all available TKIs.
Donor source: Matched sibling donor preferred; matched unrelated donor, haploidentical, or cord blood are alternatives. Australian Bone Marrow Donor Registry (ABMDR) facilitates unrelated donor searches.
Conditioning: Reduced-intensity conditioning (RIC) increasingly used given older age of many CML patients.
Outcomes: 3-year OS approximately 50–70% for CP-CML post-TKI failure; worse for advanced phases.
Post-SCT: TKI may be used as maintenance post-transplant if molecular relapse occurs; donor lymphocyte infusion (DLI) is an alternative for relapse.

Treatment-Free Remission (TFR)

Selected patients with deep, sustained molecular responses may be candidates for supervised TKI cessation:

Eligibility: CP-CML treated with TKI for ≥5 years; sustained MR4 (BCR-ABL1 ≤0.01% IS) or MR4.5 (≤0.0032% IS) for ≥2 years; access to reliable qRT-PCR.
Monitoring: qRT-PCR monthly for 6 months, then every 2–3 months for at least 5 years (some centres continue indefinitely).
Outcome: Approximately 40–60% maintain undetectable molecular residual disease (UMRD); 30–50% experience molecular relapse (loss of MMR) and require TKI re-initiation — typically with rapid return to DMR.
Withdrawal symptoms: Musculoskeletal pain (TKI withdrawal syndrome) occurs in 20–30% of patients stopping imatinib; usually self-limiting.

Monitoring & Long-Term Follow-Up

Molecular Monitoring

Quantitative BCR-ABL1 RT-PCR on the International Scale (IS) is the primary tool for monitoring TKI response. Testing should be performed:

Every 3 months until MMR (≤0.1% IS) is achieved, then every 3 months for the first 3 years.
Every 3–6 months thereafter in stable responders.
Monthly during TFR.
Any confirmed >1-log increase in transcript level should prompt mutation testing and clinical reassessment.

Australian laboratories participating in the international BCR-ABL1 standardisation programme ensure results are comparable across centres. MBS Item 73304 covers quantitative BCR-ABL1 monitoring.

Laboratory Monitoring for TKI Toxicity

Test	Frequency	Relevance
FBC with differential	Weekly × 1 month → fortnightly × 2 months → monthly → 3-monthly	Cytopenias (all TKIs); monitor for disease progression
LFTs (ALT, AST, bilirubin)	Monthly × 3 months → 3-monthly	Hepatotoxicity (imatinib, nilotinib)
Lipid profile	Baseline, 3-monthly on nilotinib	Nilotinib-associated dyslipidaemia and accelerated atherosclerosis
Fasting glucose / HbA1c	Baseline, 3–6-monthly on nilotinib	Hyperglycaemia with nilotinib
ECG (12-lead)	Baseline, day 3 & 7 with nilotinib; as clinically indicated with dasatinib	QTc prolongation (nilotinib); pleural effusion screening (dasatinib)
CXR	If respiratory symptoms on dasatinib	Pulmonary arterial hypertension (rare but serious with dasatinib)
Echocardiogram	Baseline and as indicated (ponatinib)	Vascular events screening with ponatinib

Cardiovascular Risk Management

Second-generation TKIs (particularly nilotinib and ponatinib) are associated with increased cardiovascular risk. All patients should have:

Baseline cardiovascular risk assessment (Australian absolute CVD risk calculator).
Aggressive management of modifiable risk factors: smoking cessation, hypertension control, statin therapy for dyslipidaemia, diabetes management.
Nilotinib is generally avoided in patients with significant pre-existing cardiovascular or peripheral vascular disease.
Ponatinib requires careful cardiovascular risk–benefit assessment; dose reduction strategies (30 mg or 15 mg in responders) mitigate vascular risk.

Special Populations

🤰 Pregnancy

All TKIs Contraindicated in pregnancy (Category D). Teratogenic — imatinib causes exomphalos, renal anomalies; dasatinib/nilotinib similarly. Discontinue TKI when pregnancy confirmed (ideally pre-conception planning).

Management in pregnancy If CP-CML with stable response: TKI cessation with close monitoring (qRT-PCR monthly). Most patients remain in CHR throughout pregnancy. Interferon-alpha (IFN-α) may be used in 2nd/3rd trimester if needed. Leukapheresis for extreme hyperleucocytosis. Avoid hydroxyurea in first trimester.

Post-partum Restart TKI promptly after delivery. Breastfeeding contraindicated while on TKI therapy.

👶 Paediatric CML

Epidemiology ~3% of paediatric leukaemias; median age 12–14 years. Presentation often more aggressive than adults.

Imatinib 260 mg/m²/day PO (max 400 mg). PBS-subsidised for paediatric use. Growth impairment is a recognised concern — monitor height velocity.

Dasatinib 60 mg/m²/day PO (max 100 mg). TGA-approved for paediatric CP-CML ≥1 year. Preferred if ELTS high-risk.

Allo-SCT Considered more readily in paediatric patients — lifelong TKI side effects are a greater concern in children. Discuss at TKI failure or if deep response not achieved.

👴 Elderly

TKI choice Imatinib is generally preferred in elderly patients due to its favourable long-term safety profile and lower cardiovascular risk compared to nilotinib. Dose adjustment may be needed for comorbidities.

Comorbidity considerations Assess cardiac, hepatic, and renal function. Avoid nilotinib in patients with significant vascular disease. Monitor for polypharmacy drug interactions.

🫘 Renal Impairment

Imatinib Reduce dose by 50% if CrCl <20 mL/min or dialysis. Limited data — monitor FBC closely. Not significantly dialysed.

Dasatinib No dose adjustment; limited data in severe CKD.

Nilotinib No dose adjustment; not studied on dialysis.

🫁 Hepatic Impairment

General All TKIs undergo hepatic metabolism (primarily CYP3A4). Dose reduction or avoidance required in moderate-severe hepatic impairment. Monitor LFTs closely.

Bosutinib Contraindicated in Child-Pugh C.

🛡️ Immunocompromised

TKI immunosuppressive effects TKIs can cause neutropenia and lymphopenia. Dasatinib may cause T-cell and NK-cell dysfunction, increasing infection risk. Monitor for opportunistic infections. Dasatinib-associated large granular lymphocyte (LGL) expansion is an immune-mediated phenomenon associated with good response.

Allo-SCT recipients Immunosuppression from conditioning and GVHD prophylaxis. Post-SCT TKI use should be coordinated with transplant team.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

While CML incidence among Aboriginal and Torres Strait Islander Australians appears broadly comparable to the non-Indigenous population, significant disparities exist in presentation stage, access to haematology care, and long-term outcomes. The following considerations are essential for equitable CML management.

Delayed presentation

Aboriginal and Torres Strait Islander patients may present at more advanced disease stage due to delays in primary care presentation, limited awareness of CML symptoms, and diagnostic delays. A lower threshold for FBC and specialist referral is warranted.

Remote & very remote access

Patients in remote NT, QLD, WA, and SA communities face significant barriers to accessing haematology centres. Telehealth consultations (MBS Items 91801–91827) and medication delivery via Remote Area Aboriginal Health Services (RAAHS) are essential. Outreach haematology clinics improve engagement.

TKI adherence

Adherence to daily TKI therapy is critical for optimal outcomes. Community pharmacy partnerships, Webster-pak delivery, Aboriginal Health Worker support, and culturally safe education programmes improve medication adherence. Sub-optimal adherence (<90% pill intake) is associated with inferior molecular response and resistance.

PCR monitoring access

qRT-PCR monitoring every 3 months requires reliable specimen transport from remote communities. Dried blood spot (DBS) PCR testing, now validated for BCR-ABL1 quantitation, may facilitate monitoring where venous blood transport is impractical.

Comorbidity burden

Higher prevalence of diabetes, chronic kidney disease, cardiovascular disease, and hepatitis B in Aboriginal and Torres Strait Islander populations impacts TKI selection. Nilotinib should be used cautiously given cardiovascular risk profile. Imatinib's more favourable safety profile may be preferred. Screen for hepatitis B before starting TKI (risk of reactivation).

Cultural safety

Ensure culturally safe communication; involve Aboriginal Health Workers and Liaison Officers; respect kinship obligations and sorry business; offer face-to-face follow-up where possible. Written information should be in plain English with pictorial aids. Consider yarning-based education approaches.

Allo-SCT access

Allo-SCT requires travel to major capital city centres (Sydney, Melbourne, Brisbane, Perth, Adelaide). Financial assistance for travel and accommodation through state health department schemes and the Patient Assisted Travel Scheme (PATS) is critical. ABMDR donor representation of Aboriginal and Torres Strait Islander individuals is low — family donor evaluation should be prioritised.

Closing the Gap

CML management aligns with the National Agreement on Closing the Gap Priority Reform 1 (formal partnerships) and Priority Reform 4 (shared access to data). Cancer Australia's Optimal Care Pathway for Aboriginal and Torres Strait Islander people with cancer provides a framework for equitable CML care delivery.

📚 References

1. Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966–984.
2. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872–884.
3. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Chronic Myeloid Leukemia. Version 3.2024. Fort Washington, PA: NCCN; 2024.
4. Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34(20):2333–2340.
5. Hughes TP, Saglio G, Quintás-Cardama A, et al. BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase. Leukemia. 2015;29(9):1832–1838.
6. Lipton JH, Chuah C, Guerci-Bresler A, et al. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17(5):612–621.
7. Mahon FX, Réa D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029–1035.
8. Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122(4):515–522.
9. Australian Institute of Health and Welfare (AIHW). Cancer in Australia 2021. Cancer Series No. 133. Cat. no. CAN 144. Canberra: AIHW; 2021.
10. Cancer Australia. Optimal care pathway for Aboriginal and Torres Strait Islander people with cancer. Sydney: Cancer Australia; 2018.
11. Geissler J, Gil-Fernández JJ, Olavarria E, et al. Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review. J Hematol Oncol. 2020;13(1):142.
12. Pfirrmann M, Baccarani M, Saussele S, et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia. 2016;30(1):48–56.
13. Branford S, Fletcher L, Cross NC, et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent assessment of molecular response. Leukemia. 2008;22(4):732–738.
14. Nicolini FE, Basak GW, Soverini S, et al. Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL. Leukemia. 2021;35(7):1997–2005.
15. Pharmaceutical Benefits Scheme (PBS). Schedule of Pharmaceutical Benefits. Australian Government Department of Health. Available at: https://www.pbs.gov.au. Accessed 2024.